Use of recombinant factor VIIa in inherited platelet disorders [5]

British Journal of Haematology

Volumn 125, Issue 1, 2004, Pages 95-96

  Kaleelrahman, Mohamed ^a   Minford, Adrian ^a   Parapia, Liakat Ali ^a  

^a BRADFORD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Bernard Soulier syndrome; Congenital platelet function disorders; Glanzmann's thrombasthenia; Platelet transfusion; Recombinant factor VIIa

Indexed keywords

ANTIFIBRINOLYTIC AGENT; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADULT; ALLOIMMUNIZATION; BERNARD SOULIER DISEASE; BLEEDING; CASE REPORT; CHILD; EPISTAXIS; FEMALE; GINGIVA BLEEDING; GLANZMANN DISEASE; HEALTH CARE COST; HUMAN; INFECTION RISK; LETTER; MALE; MENORRHAGIA; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOCYTE FUNCTION; THROMBOCYTE TRANSFUSION; TREATMENT OUTCOME;

ADULT; BERNARD-SOULIER SYNDROME; CHILD; FACTOR VII; FEMALE; HUMANS; INFANT; MALE; RECOMBINANT PROTEINS; THROMBASTHENIA; TREATMENT OUTCOME;

EID: 1842557944     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2004.04878.x     Document Type: Letter

References (2)

1. Almeida, A.M., Khair, K., Hann, I. & Liesner, R. (2003) The use of recombinant factor VIIa in children with inherited platelet function disorders. British Journal of Haematology, 121, 477-481.
2. Poon, M.C. & d'Orion, R. (2000) Recombinant activated factor VII (NovoSeven) treatment of platelet-related bleeding disorders. International Registry on Recombinant Factor VIIa and Congenital Platelet Disorders Group. Blood Coagulation Fibrinolysis, 11(Suppl. 1), S55-S68.